Literature DB >> 19670455

Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases.

Tsung-Teh Wu1, Michael Levy, Arlene M Correa, Charles B Rosen, Susan C Abraham.   

Abstract

BACKGROUND: Biliary intraepithelial neoplasia (BilIN) represents a spectrum of proliferative and/or cytologically atypical lesions of the large intrahepatic bile ducts. BilIN is believed to be a major pathway leading to the development of intrahepatic cholangiocarcinoma (CCA) through a dysplasia-carcinoma sequence. Recently, a large interobserver agreement study in patients with hepatolithiasis, choledochal cysts, and primary sclerosing cholangitis proposed diagnostic criteria for 3 categories of BilIN based on increasing grades of nuclear atypia and loss of nuclear polarity: BilIN-1, BilIN-2, and BilIN-3. BilIN has not been systematically studied as a potential precursor lesion in patients with nonbiliary liver disease, despite the epidemiologic association between intrahepatic CCA, hepatitis C infection (HCV), and alcohol (EtOH) consumption.
METHODS: We submitted 12 paraffin blocks targeted to the large intrahepatic and hilar ducts in each of 244 explanted livers with EtOH cirrhosis (n = 94), HCV cirrhosis (n = 44), EtOH + HCV (n = 26), and noncirrhotic controls (eg, livers removed for metabolic disorders, massive hepatic necrosis) (n = 80), and classified all bile duct profiles as normal/reactive, metaplastic, or BilIN-1, -2, or -3 (flat or papillary).
RESULTS: Livers transplanted for EtOH and EtOH + HCV cirrhosis had the highest prevalence of BilIN, greater numbers of ducts with BilIN, and a shift toward higher grades of BilIN as compared with HCV alone and with noncirrhotics. In EtOH, the highest grades of BilIN were 0 = 3%, BilIN-1 = 35%, BilIN-2 = 57%, BilIN-3 = 4%; in EtOH + HCV: 4%, 38%, 54%, 4%; in HCV: 18%, 55%, 20%, 7%; and in noncirrhotics: 45%, 39%, 16%, 0%, respectively. In both univariate and multivariate analysis, EtOH (P < .001), EtOH + HCV (P < .001), and HCV cirrhosis (P < .001) were all significant predictors of BilIN grade. Multifocal BilIN (>/=10 ducts) was present in 91% of EtOH, 92% of EtOH + HCV, and 61% of HCV cirrhosis, as compared with only 34% of noncirrhotics (P values of <.0001, <.001, and .002, respectively, in both univariate and multivariate analysis). Papillary or micropapillary architecture of BilIN was also more common in EtOH (47%) than in EtOH + HCV (19%), HCV (23%), or noncirrhotics (17%) (P < .001 in both univariate and multivariate analysis). BilIN-3 occurred only in the setting of cirrhosis (8 of 164 cirrhotic livers, 5%) and was associated with CCA (2 cases) or mixed hepatocellular/CCA (1 case) elsewhere in the liver.
CONCLUSIONS: In aggregate, these findings provide morphologic support for the epidemiologic role of alcohol and HCV in the development of CCA. 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19670455     DOI: 10.1002/cncr.24471

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

Review 1.  Pathology of intrahepatic cholangiocarcinoma.

Authors:  Sandrine Vijgen; Benoit Terris; Laura Rubbia-Brandt
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Biliary intraepithelial neoplasia: a case with benign biliary stricture.

Authors:  Wonkyung Jung; Baek hui Kim
Journal:  Korean J Hepatol       Date:  2011-12

Review 3.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 4.  Surgical treatment for intrahepatic cholangiocarcinoma.

Authors:  Takahiro Uenishi; Takatsugu Yamamoto; Shigekazu Takemura; Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2014-02-15

5.  Does a combination of opisthorchiasis and ethyl alcohol consumption enhance early cholangiofibrosis, the risk of cholangiocarcinoma?

Authors:  Pranee Sriraj; Ratchadawan Aukkanimart; Thidarut Boonmars; Amornrat Juasook; Pakkayanee Sudsarn; Nadchanan Wonkchalee; Chawalit Pairojkul; Sakda Waraasawapati; Porntip Laummaunwai; Sirintip Boonjaraspinyo
Journal:  Parasitol Res       Date:  2013-06-27       Impact factor: 2.289

6.  Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

Authors:  Michael R O'Dell; Jing Li Huang; Christa L Whitney-Miller; Vikram Deshpande; Paul Rothberg; Valerie Grose; Randall M Rossi; Andrew X Zhu; Hartmut Land; Nabeel Bardeesy; Aram F Hezel
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

Review 7.  Preneoplastic conditions underlying bile duct cancer.

Authors:  Lena Sibulesky; Justin Nguyen; Tushar Patel
Journal:  Langenbecks Arch Surg       Date:  2012-03-06       Impact factor: 3.445

Review 8.  Hilar cholangiocarcinoma: pathology and tumor biology.

Authors:  Dong Kuang; Guo-Ping Wang
Journal:  Front Med China       Date:  2010-11-25

Review 9.  Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review.

Authors:  Sirio Fiorino; Letizia Bacchi-Reggiani; Dario de Biase; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Giorgia Acquaviva; Luca di Tommaso; Arrigo Bondi; Michela Visani; Sergio Sabbatani; Laura Pontoriero; Carlo Fabbri; Andrea Cuppini; Annalisa Pession; Elio Jovine
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

10.  Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma.

Authors:  Mark Ettel; Ogechukwu Eze; Ruliang Xu
Journal:  World J Hepatol       Date:  2015-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.